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Summary.-The effects are reported of a combination therapy of i.v. C. parvum and
cyclophosphamide on the survival time and immune responses of patients with
inoperable squamous-cell carcinoma of the bronchus. The immune status of the
patients was evaluated by determining the antibody response to C. parvum, the E and
EAC rosettes, the PHA response of blood lymphocytes, the skin-test reactivity to
Candida and PPD, the response to DNCB and the chemotaxis and NBT-dye reduction
capacity of neutrophil leucocytes.
The survival time of patients treated with the combination therapy was found to be
significantly shorter than that of untreated patients and of those receiving cyclo-
phosphamide only. Severe side effects were observed after C. parvum infusions, with
no decrease on repeated administration. The effect of C. parvum on the different
immune parameters of cyclophosphamide-treated patients was negligible, though
there was a normal antibody response to C. parvum.
IN NON-RESECTABLE squamous-cell car-
cinoma of the bronchus the survival time
is low. Although some benefit may be
achieved by irradiationandchemotherapy,
the median survival time is only slightly
increased (Carbone et al., 1970). There has
been evidence that stimulation of the
immune system with bacterial toxins can
favourably modify tumour growth (Nauts,
1969). Corynebacterium parvum is known
to be a potent stimulator of the immune
system (Halpern et al., 1963) and its
administration in combination with cyto-
statics was reported to be of value in
animal tumour models (Fisher et al.,
1975a) and in human neoplastic disease
(Israel & Edelstein, 1975; Presant et al.,
1976; Pinsky et al., 1978). Israel and
Edelstein (1975) noted a significant in-
crease in the survival time of patients
with carcinoma of the bronchus treated
with a 5-drug combination chemotherapy
and C. parvum s.c. as compared to the
survival time of similar cases treated with
cytostatics alone. They also found that
C. parvum improved the "hematopoietic
tolerance to chemotherapy, i.e. the num-
ber of therapeutic interruptions due to
leukopenia could be reduced to half in the
C. parvum-treated group. Their observa-
tions were confirmed by others (Dimitrov
et al., 1978). It is well established that
chemotherapy not only decreases the
number of peripheral white cells, but also
influences the functions of these cells
(Haskell, 1977).
This report describes a study on the
effect of C. parvum on the survival time
and the function of the immune system of
cyclophosphamide-treated patients suffer-
ing from inoperable squamous-cell car-
cinoma of the bronchus. Cyclophosph-
amide (CY) was given i.v. either alone at
fortnightly intervals or in combination
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with C. parvum. Regarding the route of
administration it is known from animal
studies that the effect of this immuno-
stimulant is most marked after i.v. or i.p.
injection, whereas the s.c. route was much
less effective (Woodruff et al., 1975; Fisher
et al., 1975b). C. parvum was therefore
given by i.v. infusion. It was infused a few
hours after CY, since it has been reported
that an effective therapy regime could be
achieved by administration of both CY
and C. parvum on the same day (Fisher
et cal., 1975b). As it is still a matter of
conjecture whether CY alone given i.v. is
of value in the treatment of squamous-
cell carcinoma of the bronchus (Cohen,
1978) we also included in this study a
patient group left untreated. This latter
group enabled us to evaluate not only the
effect of the given dose of CY on the sur-
vival time, but also on the functions ofthe
immune system.
During the study it became evident that
the survival time of patients treated with
the combination therapy ofC. parvum and
CY was significantly shorter than that
recorded in the other 2 patient groups.
This forced us to terminate the study
prematurely, so that data from a limited
number of patients are reported.
PATIENTS AND METHODS
Patients.-Twenty-three male patients
with non-resectable squamous-cell carcinoma
of the bronchus (Stage Ilb and III) and with
a Karnofsky performance score of 80 to 100
were studied, after informed consent had
been obtained. The median age was 62 years,
range 45-76. None of the patients had re-
ceived previous chemotherapy or radio-
therapy, or had contraindications for C.
parvum treatment, such as autoimmune
disease, hypertension, cardiovascular disease,
severe pulmonary insufficiency, intercurrent
infections or the use of barbiturates.
The patients were randomly allocated to
3 groups, using a computer-generated pseudo-
random table, in such a way that an identical
age distribution was obtained in each group.
The first group received both CY and C.
parvum, the second group CY alone and the
third group neither agent.
Cytostatic therapy.-20 mg/kg CY (Endoxan
Asta, Brackwede, Germany) was given i.v.
at fortnightly intervals. When total white-
cell counts dropped below 4 x 109/1 or throm-
bocytes below 100 x 109/1 the dose was
reduced to half. The treatment was stopped
w"hen total white cells or thrombocytes
reached a level of 2 x 109/1 or 75 x 109/1
respectively.
Immunotherapy.-C. parvum (Burroughs
Wellcome, Batch No. BL 3935) 7-5 mg/M2
body surface, was given i.v. at monthly
intervals. The vaccine was administered by a
2h infusion a few h after the administration
of CY. No antipyretics or steroids were given
during the treatment. Side effects were re-
corded during the first 24 h. Total white cell
and lymphocyte counts were routinely esti-
mated 5 days before the first administration
of C. parvum and/or CY (Day -5) and 8 and
70 days after starting therapy.
Antibodies to C. parvum.-Blood was
collected 5 days before and 12 days after the
first administration of C. parvum for estima-
tions of serum antibodies to C. parvum with
an ELISA as described by Ruitenberg et al.
(submitted for publication).
E/EAC rosettes.-Lymphoid cells were
isolated on a Ficoll-Isopaque gradient
(Boyum, 1968) using freshly drawn de-
fibrinated blood collected 5 days before and
8 and 70 days after starting therapy. Differ-
ential cell counts on stained smears gave 80%
or greater lymphocyte purity. The percentage
of E- and EAC-rosette-forming cells in the
lymphoid cell suspensions were estimated
by the method described by Zeylemaker et al.
(1974). The absolute numbers were calculated
by multiplication from the total peripheral
lymphocyte count.
Phytohaemagglutinin (PHA) stimulation.
The blastogenic response to the mitogen
PHA of Ficoll-Isopaque isolated and cryo-
preserved (Cryoson, Midden-Beemster, The
Netherlands) lymphoid cells obtained 5 days
before and 5 days after starting therapy was
estimated. The use of cryopreservation tech-
niques made it possible to evaluate simul-
taneously both pre- and post-treatment
response. The lymphoid cells were cultured in
Linbro microplates (Linbro Hamden, Conn.,
U.S.A.) using 4 x 104 viable cells per well in
0-15 ml HEPES-buffered RPMI (Gibco,
Glasgow) supplemented with 20% inactivated
pooled human serum and antibiotics, either
with or without PHA (Wellcome Reagents
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Ltd, Beckenham, Kent) added to give
10 ,ug/ml. This method, using a 3-day incu-
bation, 24h 3H-thymidine pulse and a
Titertek harvester was previously described
by Du Bois et al. (1974).
The results are expressed as mean counts
per minute (ct/min) per culture.
Skin tests.-Skin reactivity to Candida
(1 mg/ml; H.A.L. allergen lab. Haarlem,
The Netherlands) and PPD (10 u/ml; R.I.V.,
Bilthoven, The Netherlands) was determined
by intracutaneous injection of 01 ml of each
preparation into the forearm. Tests were
carried out 5 days before and 5 and 70 days
after starting therapy. The results are
accorded as average diameter of induration
in millimeters of 2 right-angle measurements
72 h after antigen injection.
DNCB sensitization.-Contact sensitivity
to dinitrochlorobenzene (DNCB) was induced
by epicutaneous application of 2 mg DNCB
in 04 ml acetone 2 days before the first
administration of C. parvum and/or CY. A
challenge with 10 jtg DNCB in acetone was
carried out (patch test) 12 and 70 days after
starting therapy. The response was evaluated
after 3 days and classified as negative or
positive (erythema and/or bulla).
Chemotaxi8 and quantitative Nitro Blue
Tetrazolium-dye reduction of neutrophil leutco-
cytes.-Both assays were carried out with
neutrophils 5 days before and 5 and 70 days
after starting therapy. They were isolated
from the cell pellet obtained with the Ficoll-
Isopaque separation technique described
above, using NH4C1 for erythrocyte lysis
(Weening et al., 1974).
Neutrophil chemotaxis was determined
according to Wilkinson (1974) using modified
Boyden chambers and Millipore membranes
(Millipore Inc., Bedford, Massachusetts,
U.S.A.) of 5 Htm pore size. The cells were
allowed to migrate for 20 min into the mem-
branes towards a Gey solution, or towards
0.4% casein (Hammersten, Merck, Darm-
stadt, Germany) in Gey solution. The dis-
tance of migration into the membranes was
recorded using the leading front method
(Zigmond & Hirsch, 1973). The quantitative
NBT-dye reduction capacity of the neutro-
phils was determined according to the
method described by Drexhage et al. (1978)
but using 5 x 106 leucocytes and foetal-calf-
serum-supplemented medium. The reaction
was allowed to proceed for 10 min. The
optical densities (OD) at 509 nm of 2 ml
42
pyridine extracts of the granulocytes were
determined (spectrophotometer, Eppendorf
1101 M, Hamburg, Germany).
RESULTS
The course of the Karnofsky perform-
ance score recorded in each patient and
their survival times are shown in Fig. 1.
Median survival times were 125 days in
the group treated with the combination
therapy, 245 days after therapy with CY
only, and 277 days in patients left un-
treated. The difference between the com-
bination therapy and the CY therapy
group was significant at a 5% level
(Wilcoxon test). It has been reported that
only a difference significant at the 1%
level would merit a decision to stop a trial
(Pocock, 1978) but continuing was un-
justifiable in our opinion, since consider-
able side effects were found (Table I). A
febrile response was evident in almost all
patients, whereas chills, an increased
pulse rate and mild dyspnoea were seen
after most of the C. parvum infusions. A
few patients had nausea and vomiting,
changes in blood pressure and headache.
All these side effects subsided within 24 h.
No obvious decrease in the complaints
was noted after a second or third C.
parvum infusion.
One of the patients in the C. parvum-
treated group died 10 h after the second
administration. Thorough medical ex-
amination before entrance into the trial
of this patient had not revealed any
contraindication for C. parvum therapy.
However, at necropsy an old myocardial
infarction and arteriosclerotic coronary
insufficiency were found to be present.
Antibodies to C. parvum were measured
5 days before and 12 days after the first
administration. Ratios of post- to pre-
treatment titres are given in Fig. 2. As can
be seen, all patients who had received
C. parvum showed a rise in titre, whereas
in the 2 other groups only 1 and 2
patients exhibited a ratio of 1-1*5.
The total white cell, lymphocyte and
the E- and EAC-rosette counts before and
after treatment are listed in Table II. No
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FIG. 1.-The course of the Karnofsky performance score and the survival time of each patient
(a) treated with cyclophosphamide and C. parvum, (b) treated with cyclophosphamide only and
(c) left untreated.
TABLE I.-Side effectb
tration of 7.5 my
surface, expressed a
patients/total numbe
Temperature > 38 5°C
Chills
Pulse rate > 100/min
Respiration rate > 30/min
Nausea/vomiting
Systolic bloodpressure
> 175 mmHg
Diastolic bloodpressure
> 100 mmHg
Headache
differences were founc
in patients with bror
before therapy and tl
viduals. In patients 1
S of the i.v. adminis- total numbers of white cells, lymphocytes
C. parvum/m2 body and E- and EAC-rosette-forming cells
,s number of positive were reduced to half at 8 and 70 days
r ofpatients after starting therapy. Identical results,
Administration namely reductions to half, were obtained
A
3 in the group treated with the combination
1st 2nd 3rd therapy. It is of interest that in the latter
9/9 6/6 2/3 group the dose of CY hadto be reduced as
8/9 5/6 2/3 many times as in the group treated with
6/9 4/5 0/3 CY alone (i.e. in 20% of the administra-
5/6 2/6 2/3 tions).
4/9 3/6 2/3 The blastogenic response of blood
lymphocytes to PHA was significantly
3/9 1/6 0/3 lower in the carcinoma patients than in
healthy individuals (Table III). No
changes in PHA response were induced by
I between the counts cytostatic treatment alone or cytostatic
ichogenic carcinoma treatment in combination with C. parvum.
hose of healthy indi- The skin reactivity to Candida and
treated with CY the PPD was also studied in these patients
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FIG. 2.-The ratios of the post- and pre-
treatment antibody titres to C. parvum of:
patients treated with cyclophosphamide in
combination with C. parvum, patients
treated with cyclophosphamide only, and
patients left untreated.
TABLE III.-Phytohaemagglutinin blasto-
genesis
Healthy individuals
Patients before
treatment
Patients treated with
cyclophosphamide
and C. parvum 5
Patients treated with
cyclophosphamide 5
Patients left
untreated 5
[3H]TdR uptake (ct/min)
n Mean + s.d. Median
22 5980+ 4960 4290
13 2750+ 1770 2160*
7 3280+ 1850 2810
5 2230+ 1690 1930
3 3580+ 2250 2790
n =number of patients, s.d. =standard deviation.
* A statistically significant difference (Wilcoxon
test P < 0.05) between carcinoma patients before
treatment and healthy individuals.
and the number and the diameter of the
positive tests were recorded. No significant
differences were found between the skin
reactivity of carcinoma patients before
therapy (Candida 66% and PPD 47%
positive) and the skin-test reactivity of
non-carcinoma patients (Candida 61%
and PPD 35% positive). In patients left
without cytostatic and/orimmunotherapy,
the diameter of induration of the skin
tests to these antigens showed a tendency
to decline in the 2-month follow up, but
the number of tests was too small for
statistical evaluation.
With regard to the DNCB sensitization,
no differences were found between the 3
groups of patients 14 days after sensitiza-
tion, 70% ofthe patients in all 3 groups
had become sensitive. At Day 70, 4/4
untreated patients had become sensitive,
whereas in the 2 other groups 2/3
(combination therapy) and 2/5 (cytostatic
therapy alone) responded to a DNCB
challenge, but again the number of tests
was too small for statistical evaluation.
The chemotaxis and the NBT-dye
reduction capacity of neutrophil leuco-
cytes ofthe carcinoma patients were com-
parable to those of healthy individuals.
Whatever therapy the patients received,
it had no influence on the chemotaxis or
NBT-dye reduction test.
DISCUSSION
It became evident during this study
that bronchial carcinoma patients treated
with a combination therapy of i.v. C.
parvum and CY showed a poor survival
time. Moreover the treatment with C.
parvum produced severe side effects during
the first few hours after administration.
Similar side effects were reported by
Fisher et al. (1976). Decreases in these side
effects after repeated administrations as
described by Israel (1974) were not found.
The immune status of the carcinoma
patients was compared with that of
healthy individuals. No differences were
found regarding the number of peripheral
white cells, lymphocytes, E and EAC
rosettes, skin reactivity to Candida and
PPD, ability to become sensitized to
DNCB and the functions of neutrophil
leucocytes as measured by chemotaxis and
the quantitative NBT-dye reductions
assay. However, the PHA blastogenesis
10
8
6
4
2
0
0
0
a
Q
.2
oi
I I
614HARMFUL EFFECTS OF I.V. C. PAR 1-UM
was lower in the carcinoma patients.
Al-Sarraf et al. (1972) and Thatcher et al.
(1979) also demonstrated that the in vitro
blastogenic transformation of lympho-
cytes by PHA was impaired in patients
with solid tumours, especially with ad-
vanced neoplasia. Regarding the number
of lymphocytes and T cells in tumour-
bearing patients, there is much confusion
in the literature. Some investigators report
normal ranges of T lymphocytes (Wybran
& Fudenberg, 1976; Middlekoop et al.,
1976) whereas others find decreased num-
bers (Dellon et al., 1975; Roberts et al.,
1977) mostly depending on technical
variables. The suppression of neutrophil
function in carcinoma patients, described
by Bauim (I1975), was not confirmed in this
study.
To evaluate the effect of the cytostatic
therapy and the combination therapy on
the immune status of the patients, we
investigated the described parameters
after one administration of CY and C.
parvum and after 2 months of therapy.
In patients left untreated no significant
change was found in any of the immune
parameters studied in the 2-month follow
up, though the skin reactivity to PPD and
Candida tended to decline. This is in agree-
ment with the findings of Brugarolas et al.
(1973) who reported a close relationship
between the impairment of delayed skin
reactivity and the extent of the disease.
Patients treated with CY only showed a
survival time comparable with that of
untreated patients. This indicates the
ineffectiveness of this type of cytostatic
treatment. The impaired PHA response
found in patients before therapy did not
change after CY administration. This con-
tinued suppression of PHA response may
reflect the poor survival time, since
Cheema & Hersh (1971) reported a re-
bound of in vitro PHA blastogenesis in
patients showing a regression of their
malignancy after chemotherapy. Regard-
ing the responsiveness to DNCB the
administration of CY has been shown to
be able to influence the development of
delayed hypersensitivity in experimental
animals. Suppression and enhancement of
the induction of delayed hypersensitivity
have been reported, depending on the
dose and schedule of the CY administered
(Turk et al., 1976). It is evident that in our
study theinfluence ofCYon T-lymphocyte
function was minimal.
WVith regard to the addition of C.
parvum immunotherapy to cytostatic
treatment, no effect on any ofthe immune
parameters was detected, though a normal
antibody response to C.parrum was noted.
It became clear over the last few years
that the immunostimulatory effects of
anaerobic coryneform bacteria depends
especially on their ability to stimulate the
functions of cells of the mononuclear
phagocyte system (Wilkinson, 1975).
Therefore we also studied the effect of
7.5 mg C. parvumI/m2 i.v. on 2 particu-
lar functions of blood monocytes (i.e.
spreading and antibody-dependent cyto-
toxicity) in a few patients suffering oat-
cell carcinoma of the bronchus. The
results obtained in these C. parvum-
infused patients were again not different
from the results obtained in non-infused
patients when tested at 14 days (un-
published results).
The negative results in the C. parvum-
and CY-treated patients are in sharp con-
trast to the positive results reported by
Israel & Edelstein (1975) and Dimitrov
et al. (1978). However, they used a 5-drug
combination chemotherapy and adminis-
tered C. parvum s.c. Probably the route of
administration is of importance. Pinsky
et al. (1978) also reported a beneficial effect
of s.c. C. parvum in advanced carcinoma
of the breast, and preliminary results of a
similar treatment in patients with a
carcinoma of the cervix uteri in our hos-
pital show an enhanced response to
DNCB (to be published). There are also
indications that the dose of the i.v. C.
parvum is ofimportance. Using a low dose
(2 mg/M2) Thatcher et al. (1979) reported
an increase in T-cell numbers and PAH
blastogenesis one week after a single
immunization, whereas Minton et al. (1976)
found no increase in these parameters in
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patients with a carcinoma of the breast
after an infusion of a higher dose (5 mg
C. parvum/m2). Furthermore, the interval
between the administration of Cy and i.v.
C. parvum used in this study (2 h) may
have been too small. Extremely toxic
effects and little anti-tumour activity have
been reported in mice when the interval
was zero (Currie & Bagshawe, 1970).
However, in other animal studies, effective
therapy regimes could be achieved when
both agents were given on the same day
(Fisher et at., 1975b). The anti-tumour
activity of i.v. C. parvum is probably
stronger when given 4 days after CY
(Scott, 1979).
In conclusion, our results indicate that
one must be very careful in the use of a
relatively high dose of i.v. C. parvum in
combination with chemotherapy. Harmful
effects can occur.
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